Low cost, low footprint, expandable automated biobanking solutions
Poster Jan 21, 2013
James Craven, Chris Morris, Maud Godfrey, Danielle Miller
In a large number of academic research centres and small pharmaceutical or biotech companies, biological sample storage remains a manual process requiring meticulous sample labelling, robust data logging, accurate placement and retrieval.
As the sample library grows, the acquisition of additional freezers can place strain on laboratory space or storage areas. Manual placement and retrieval of samples from large libraries not only increases the potential for error but can inhibit sample processing speeds necessary to satisfy research flow or customer delivery schedules.
Manual placement, search and retrieval samples often requires scientists to spend lengthy periods of time handling samples in freezers or standing in cold storage rooms. Therefore the ability to automate sample dispensing and processing whilst ensuring robust sample labelling and tracking is invaluable, significantly reducing the effort and turn-around time of compound storage and retrieval.
TTP Labtech’s comPOUND storage modules provide low footprint, cost-efficient automated biobanking capabilities .They also have the ability to individually cherry pick samples whilst not disturbing the internal storage environment, ensuring the integrity of unselected samples.
This poster presents a case study where TTP Labtech’s comPOUND biobanking storage modules have been successfully employed by Abcam, a worldwide supplier of high quality antibodies, proteins, peptides, lysates and assay kits. In this company, the turnaround time of sample placement and retrieval is an essential component for high quality service to its customers.
We highlight a number of features of comPOUND which have proved to be of significant value during the development of this rapidly expanding company and helped to ensuring high quality customer service and support.
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE